372 related articles for article (PubMed ID: 25966424)
21. p53 Mutations in human cholangiocarcinoma: a review.
Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD
Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419
[TBL] [Abstract][Full Text] [Related]
22. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
I Ilyas S; Borad MJ; Patel T; Gores GJ
Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma.
Chiang NJ; Shan YS; Hung WC; Chen LT
Int J Biochem Cell Biol; 2015 Oct; 67():110-4. PubMed ID: 26100596
[TBL] [Abstract][Full Text] [Related]
24. [The role of molecular genetic factors in the development of cholangiocellular carcinoma].
Chulkova SV; Loginov VI; Podluzhnyi DV; Egorova AV; Syskova AY; Semichev DG; Gladilina IA; Kudashkin NE
Arkh Patol; 2022; 84(3):76-83. PubMed ID: 35639847
[TBL] [Abstract][Full Text] [Related]
25. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.
Farazi PA; Zeisberg M; Glickman J; Zhang Y; Kalluri R; DePinho RA
Cancer Res; 2006 Jul; 66(13):6622-7. PubMed ID: 16818635
[TBL] [Abstract][Full Text] [Related]
26. The molecular pathogenesis of cholangiocarcinoma.
Berthiaume EP; Wands J
Semin Liver Dis; 2004 May; 24(2):127-37. PubMed ID: 15192786
[TBL] [Abstract][Full Text] [Related]
27. Cholangiocarcinoma: new insights into disease pathogenesis and biology.
Braconi C; Patel T
Infect Dis Clin North Am; 2010 Dec; 24(4):871-84, vii. PubMed ID: 20937455
[TBL] [Abstract][Full Text] [Related]
28. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
Braconi C; Roessler S; Kruk B; Lammert F; Krawczyk M; Andersen JB
Liver Int; 2019 May; 39 Suppl 1():32-42. PubMed ID: 30829432
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of microRNA-203 in cholangiocarcinoma.
Li J; Gao B; Huang Z; Duan T; Li D; Zhang S; Zhao Y; Liu L; Wang Q; Chen Z; Cheng K
Int J Clin Exp Pathol; 2015; 8(8):9512-6. PubMed ID: 26464713
[TBL] [Abstract][Full Text] [Related]
30. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
31. Molecular aspects of cholangiocarcinoma.
Kiguchi K
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
33. Cholangiolocellular Carcinoma With "Ductal Plate Malformation" Pattern May Be Characterized by ARID1A Genetic Alterations.
Sasaki M; Sato Y; Nakanuma Y
Am J Surg Pathol; 2019 Mar; 43(3):352-360. PubMed ID: 30520820
[TBL] [Abstract][Full Text] [Related]
34. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.
Nakagawa H; Hayata Y; Yamada T; Kawamura S; Suzuki N; Koike K
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29895797
[TBL] [Abstract][Full Text] [Related]
35. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
[No Abstract] [Full Text] [Related]
36. Role of molecular genetics in the clinical management of cholangiocarcinoma.
Normanno N; Martinelli E; Melisi D; Pinto C; Rimassa L; Santini D; Scarpa A
ESMO Open; 2022 Jun; 7(3):100505. PubMed ID: 35696744
[TBL] [Abstract][Full Text] [Related]
37. Role of epigenetic alterations in cholangiocarcinoma.
Tischoff I; Wittekind C; Tannapfel A
J Hepatobiliary Pancreat Surg; 2006; 13(4):274-9. PubMed ID: 16858537
[TBL] [Abstract][Full Text] [Related]
38. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
[TBL] [Abstract][Full Text] [Related]
39. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
40. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]